Monoclonal antibody-drug conjugateFDA-approvedSecond-line
Brentuximab vedotin
How it works
Binds to the CD30 protein on cancer cells, delivering a toxic agent that kills the cells.
Cancer types
Leukemia— CD30-positive
Efficacy
In clinical trials, around 75% of CD30-positive patients achieved an objective response, with a median progression-free survival of approximately 1 year.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.